How critical is orphan designation to a biotech working towards bringing a new therapy to market? There are significant financial benefits associated with orphan designation that can help a small company to keep the lights on during the development process.
So what happens to a company’s orphan drugs strategy when that designation is taken away? In this article based on our webinar with Will Lewis, CEO at Insmed, he talks about how the company moved from being an orphan drugs company to an “orphans-plus” approach with the launch. He also discusses potential changes to the Orphan Drug Act, Insmed’s future plans, and the principles that underpin the company’s approach.
